Alnylam

Moderna hits back at Alnylam's 'baseless' patent infringement claims
Moderna hits back at Alnylam's 'baseless' patent infringement claims
Fierce Pharma
Moderna Therapeutics
Alnylam
MRNA
vaccines
legals
Flag link:
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
BioPharma Dive
Alnylam
Regeneron
clinical trials
Alzheimer's disease
ALN-APP
Flag link:
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Ionis Pharmaceuticals
AstraZeneca
eplontersen
Alnylam
ATTR
Flag link:
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Flag link:
JPM Day 1: Highlights
JPM Day 1: Highlights
BioSpace
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Insmed, Alnylam and others make Science's list of top 20 biopharma employers
Insmed, Alnylam and others make Science's list of top 20 biopharma employers
Endpoints
employers
Inbsmed
Alnylam
Regeneron
Incyte
Flag link:
Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA
Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA
BioSpace
Sanofi
Alnylam
earnings
Inflation Reduction Act
legislation
drug pricing
Flag link:
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Pharmaphorum
Alnylam
RNAi
vutrisiran
Stargardt disease
Inflation Reduction Act
drug pricing
Flag link:
The gloom deepens for biopharma stocks
The gloom deepens for biopharma stocks
EP Vantage
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Flag link:
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
FDA
Alnylam
Cytokinetics
Eli Lilly
Owlet
Boston Cell Standards
Kiromic Biopharma
Entera Bio
Transcenta Holdings
Kira Pharmaceuticals
Kite Pharma
Poxel
Seneca Therapeutics
Flag link:
FDA approves label expansion of Alnylam’s Oxlumo for PH1
FDA approves label expansion of Alnylam’s Oxlumo for PH1
Pharmaceutical Business Review
Alnylam
FDAA
Oxlumo
advanced primary hyperoxaluria
PH1
Flag link:
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Fierce Pharma
Alnylam
Onpattro
Pfizer
ATTR-CM
Flag link:
Alnylam details anticipated results from heart disease drug trial
Alnylam details anticipated results from heart disease drug trial
BioPharma Dive
Alnylam
clinical trials
Onpattro
transthyretin amyloidosis with cardiomyopathy
Flag link:
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
Alnylam
antisense
ATTRv-PN
aplontersen
Flag link:
Alnylam clears phase 2 test for Regeneron-partnered nephropathy med, as it looks to play catch-up against Calliditas
Alnylam clears phase 2 test for Regeneron-partnered nephropathy med, as it looks to play catch-up against Calliditas
Fierce Biotech
Alnylam
Regeneron
Calliditas
immunoglobin A nephropathy
clinical trials
Flag link:
Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer
Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer
MedCity News
Alnylam
Pfizer
Onpattro
hATTR
Flag link:
Alnylam reveals longer wait for anticipated drug trial results
Alnylam reveals longer wait for anticipated drug trial results
BioPharma Dive
Alnylam
earnings
clinical trials
Onpattro
Flag link:
Alnylam ratchets up Pfizer, Moderna infringement fight on same day it scored new patent
Alnylam ratchets up Pfizer, Moderna infringement fight on same day it scored new patent
Fierce Pharma
legal
Alnylam
Pfizer
Moderna Therapeutics
patents
vaccines
Flag link:
Alnylam wins FDA approval of rare disease drug in step toward profitability
Alnylam wins FDA approval of rare disease drug in step toward profitability
BioPharma Dive
Alnylam
FDA
Amvuttra
hATTR amyloidosis
Flag link:

Pages